MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
2026 New Year’s Greetings from the CEO
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy